CTE is real. Chronic traumatic encephalopathy is a neurodegenerative disease recognized by the National Institute of Neurological Disorders and Stroke (NINDS) and confirmed through hundreds of post-mortem brain examinations. It has distinct biological markers that distinguish it from every other known brain disease, and researchers have established consensus diagnostic criteria defining exactly what it looks like under a microscope. The question at this point isn’t whether CTE exists, but how to detect it in living people and how common it truly is.
What Makes CTE a Distinct Disease
CTE has a unique biological signature that no other brain condition shares. The defining feature is a buildup of a misfolded protein called tau around small blood vessels deep in the folds of the brain’s outer layer (the cortex). In 2015, a panel of neuropathologists formally defined this pattern, and revised criteria in 2021 further refined it: clumps of abnormal tau in neurons, concentrated at the bottom of cortical grooves and clustered around tiny blood vessels in an irregular pattern.
This matters because skeptics have sometimes argued that CTE is just Alzheimer’s disease or normal aging. It isn’t. Researchers using a technique called cryo-electron microscopy discovered that the tau protein in CTE actually folds into a different shape than the tau found in Alzheimer’s. The CTE version also contains an unidentified molecular element attached to the tau that simply doesn’t exist in Alzheimer’s. These are structurally different diseases at the molecular level.
As CTE progresses, the tau spreads. In early stages, it stays in the cortex. Over time, it moves into deeper brain structures involved in memory and emotion, including the hippocampus, amygdala, and eventually the brainstem.
What CTE Looks Like as It Progresses
A landmark study published in the journal Brain mapped CTE across four stages based on post-mortem examinations paired with lifetime medical histories. The progression follows a recognizable pattern.
In stage I, the most common problems are headaches and difficulty paying attention. By stage II, depression or mood swings become prominent, along with short-term memory loss, impulsive behavior, and in some cases suicidal thoughts. Stage III brings more severe memory loss, executive dysfunction (difficulty planning, organizing, and following through), aggression, and trouble with spatial awareness. By stage IV, all individuals in the study had developed full dementia. Most also showed profound attention problems, language difficulties, paranoia, depression, and trouble walking. About 31% had experienced suicidal behavior at some point.
This progression can unfold over decades, often beginning years or even decades after a person’s last exposure to head impacts.
The Link to Repetitive Head Impacts
One of the most important findings in CTE research is that concussions alone don’t appear to be the primary driver. The number of years a person spent in contact sports is more strongly associated with severe tau buildup than the number of diagnosed concussions. In fact, about 16% of confirmed CTE cases had no documented history of concussion at all, suggesting that the accumulation of smaller, subconcussive hits over time is enough to trigger the disease.
This shifts the conversation significantly. It means that the routine, repetitive impacts absorbed during practices and games, not just the dramatic hits that cause visible symptoms, carry real risk. Among football players specifically, those who developed CTE had played for an average of about 3.5 years longer than those who didn’t.
How Common CTE Actually Is
Pinning down exact prevalence is tricky because CTE can currently only be confirmed after death, and the people whose brains get donated for study aren’t a random sample. Many families donate because they suspected something was wrong, which skews the numbers upward. Researchers have tried to account for this selection bias.
One analysis estimated that the cumulative incidence of CTE among professional football players is roughly 10,700 cases per 100,000 deaths. For college players, the estimate drops to about 376 per 100,000, and for those who only played through high school, roughly 5 per 100,000. When researchers modeled the broadest possible range for professional players while adjusting for donation bias, prevalence estimates ranged anywhere from about 10% to near 100%, reflecting how much uncertainty the selection problem introduces.
The pattern is clear even with that uncertainty: more years of play at higher levels of competition correlates with higher risk.
Why It Can’t Be Diagnosed in Living People Yet
The biggest gap in CTE science right now is that there is no validated way to diagnose it in a living person. The disease is confirmed only by examining brain tissue after death. This is a major limitation for treatment, research recruitment, and for individuals who want to know whether their symptoms are caused by CTE or something else.
To address this, NINDS developed consensus criteria for something called traumatic encephalopathy syndrome (TES), which is essentially the clinical presentation doctors can evaluate while a patient is alive. TES criteria are designed for research settings and intentionally favor catching potential cases rather than ruling them out, meaning they cast a wide net.
The most ambitious effort to close the diagnosis gap is the DIAGNOSE CTE Research Project, now in its second phase with $15 million in NIH funding. The study is testing a combination of blood-based biomarkers, tau-specific brain imaging (PET scans), cognitive exams, and neuropsychiatric evaluations to see whether a reliable diagnostic profile can be built. A key goal is learning to differentiate CTE from Alzheimer’s disease in clinical settings, since the two can look similar on the surface despite being biologically distinct.
What the Remaining Debate Is About
Among researchers who study neurodegenerative disease, CTE’s existence as a unique pathology is not seriously disputed. The tau signature is too distinct and too consistently linked to head impact exposure for that. What scientists do debate is more nuanced: exactly how common CTE is in the general population, what threshold of head impacts triggers it, why some people with similar exposure histories develop it and others don’t, and whether genetics or other factors play a modifying role.
There’s also ongoing discussion about the clinical significance of early-stage CTE. Some individuals with stage I pathology at autopsy had relatively few symptoms during life, raising questions about whether the earliest tau deposits always progress or whether some people’s brains tolerate a certain amount of damage without obvious decline. These are the kinds of questions that require diagnosing CTE in living people to resolve, which is exactly why the current push for biomarkers matters so much.